Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Moderna, Inc.NASDAQ: MRNA

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 401M shares rose 2.8% year over year, ahead of the +2.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.8% holds above the trailing-twelve-month pace of +2.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
401M+1.3% QoQ
Last fiscal yearDec 2025
389M+1.3% YoY
LTMSep 2026
396M+2.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.8%——
1 year+1.3%——
3-year CAGR-0.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
389M USD
Year-over-year change
+1.3%
4-year CAGR
-0.9%

Weighted Avg Shares vs competitors

How MRNA compares with its peers on the latest reported figures

  • MRNA's LTM Sep 2026 weighted avg shares of 396M shares is the 3rd highest of the 10 companies compared; the peer median is 162.41M shares.
  • Its year-over-year change of +2.3% is the 7th highest of 10, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of -0.4% compares with a peer median of +1.5%.
MRNA Competitors Peer median
Weighted Avg Shares for MRNA and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.69B +0.3%+0.4%
GSKGSK plcLTM Jun 20262.01B -1.4%+0.2%
MRNAModerna, Inc.LTM Sep 2026396M +2.3%-0.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
BNTXBioNTech SELTM Jun 2026247.64M +3.0%-0.2%
NVAXNovavax, Inc.LTM Mar 2026162.41M +3.2%+27.5%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
PCVXVaxcyte, Inc.LTM Jun 2026139.07M +7.3%+28.0%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding MRNA) 162.41M+3.1%+1.5%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.